GSK (LON:GSK) Earns Underweight Rating from JPMorgan Chase & Co.

GSK (LON:GSK)‘s stock had its “underweight” rating restated by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Tuesday, Marketbeat reports.

Separately, Berenberg Bank lowered their target price on shares of GSK from GBX 1,820 ($22.50) to GBX 1,600 ($19.78) and set a “buy” rating for the company in a report on Friday, November 29th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,805.83 ($22.32).

GSK Stock Up 0.2 %

Shares of LON:GSK opened at GBX 1,360 ($16.81) on Tuesday. GSK has a 52-week low of GBX 1,282.50 ($15.85) and a 52-week high of GBX 1,823.50 ($22.54). The company has a market capitalization of £55.49 billion, a P/E ratio of 1,203.54, a P/E/G ratio of 1.24 and a beta of 0.31. The stock’s fifty day simple moving average is GBX 1,354.65 and its 200-day simple moving average is GBX 1,482.18. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04.

Insiders Place Their Bets

In other news, insider Jonathan Symonds purchased 1,500 shares of the company’s stock in a transaction on Friday, December 20th. The shares were bought at an average price of GBX 1,315 ($16.25) per share, for a total transaction of £19,725 ($24,381.95). Insiders have acquired 8,658 shares of company stock valued at $11,950,792 over the last quarter. Insiders own 1.61% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.